Planned surgery or radiation therapy during protocol treatment
Major surgery, radiation therapy, or systemic anti-cancer therapy within 4 weeks of study treatment start
Major surgery, radiation therapy, or systemic anti-cancer therapy within 28 days of starting study treatment.
Major surgery, anti-cancer therapy, or radiation therapy within 4 weeks of study treatment
Major surgery within 28 days of starting study treatment; -or- systemic anti-cancer therapy within the lesser of 28 days or 5 half-lives of the prior therapy before starting study treatment -or- recent radiation therapy with unresolved toxicity.
Major surgery, radiation therapy or systemic anti-cancer therapy within 2 weeks of starting study treatment
Major surgery, radiation, or treatment with any other investigational drug within 2 weeks of study treatment
May have received prior radiation therapy or surgery; however, at least 21 days must have elapsed since completion of radiation therapy or surgery and subject must have recovered from all side effects at the time of registration
Pre-planned concurrent cytotoxic chemotherapy, surgery, or radiation therapy during protocol treatment; radiation therapy is not permitted while on study
Patients must have undergone radiation therapy and surgery as part of their standard of care\r\n* Stratum A: Radiation therapy must have started within 4 weeks of diagnosis by imaging or surgery, whichever is later\r\n* Stratum B: For subjects undergoing surgery for more extensive resection, radiation therapy should be started within 4-6 weeks from surgery\r\n* H3.3K27 mutation must have been confirmed in the tumor tissue in a CLIA approved laboratory
Patient must have had previous treatment with definitive surgery or radiation therapy or cryoablation
All previous cancer therapy including radiation, chemotherapy, and surgery, must have been discontinued at least 4 weeks prior to treatment in this study
Patients who have received radiation therapy, radionuclide therapy or undergone major surgery within 4 weeks of enrollment; a biopsy will not preclude a patient from starting study
PRIOR THERAPY OR SURGERY
Patients who have received radiation therapy, radionuclide therapy or undergone surgery within certain duration (4 weeks) of enrollment
Must be at least 4 weeks since treatment with standard or investigational chemotherapy, biochemotherapy, surgery, radiation, cytokine therapy, any monoclonal antibodies or immunotherapy, and recovered from any clinically significant toxicity experienced during treatment
Major surgery within 4 weeks or radiation therapy within 14 days prior to study entry
Must be recovered from any reversible side effects of prior therapy (e.g. no major surgery, no antineoplastic or experimental therapy, or no significant radiation therapy to hematopoietic sites within 4 weeks of Baseline/C1D1, and no nitrosoureas or nitrogen mustards within 6 weeks of Baseline/C1D1)
At least 2 weeks beyond prior treatment (chemotherapy, investigational drugs including small molecular inhibitors, endocrine therapy, immunotherapy and/or radiation therapy) or major surgery, and recovered from all acute toxicities to Grade 1 or less (except alopecia and peripheral neuropathy).
Patients may have received prior radiation therapy or surgery; however, at least 14 days must have elapsed since completion of radiation therapy or surgery and patient must have recovered from all side effects at the time of registration (e.g. back to baseline or grade 1)
Treatment with radiation therapy, surgery, chemotherapy, or investigational therapy within four weeks prior to study entry
Patients who have received radiation therapy, major surgery, other locoregional therapy, within 4 weeks prior to the first date of SBRT
Treatment with radiation therapy, surgery, or investigational therapy within one month prior to registration
Must be at least 4 weeks since treatment with standard or investigational chemotherapy, biochemotherapy, surgery, radiation, cytokine therapy, and 8 weeks since any monoclonal antibodies or immunotherapy, and recovered from any clinically significant toxicity experienced during treatment
Previous treatment with surgery, radiation, chemotherapy, targeted agents are allowed provided that: \r\n* Chemotherapy/major surgery was administered > 14 days before the start nivolumab\r\n* Minor surgery, radiation, or any targeted agents were administered > 7 days before the start of nivolumab
Patients must have recovered to less than grade 1 or to baseline from toxicity of prior chemotherapy or biologic therapy and must not have had major surgery, chemotherapy, radiation or biologic therapy within 2 weeks prior to beginning treatment; NOTE: Exceptions to this include events not considered to place the subject at unacceptable risk of participation in the opinion of the principal investigator (PI) (e.g., alopecia)
A minimum time period must elapse between the end of a previous treatment and start of study therapy:\r\n* 1 week from the completion of radiation therapy for brain metastases\r\n* 4 weeks from the completion of chemotherapy or any experimental therapy\r\n* 4 weeks from prior major surgery (such as open biopsy or significant traumatic injury)
Major surgery, chemotherapy, radiotherapy, or other anti-cancer therapy within 2 weeks before randomization; Note: no washout required for single dose Gamma Knife radiation
Major surgery, radiation therapy or anti-cancer therapy within 2 to 4 weeks of starting study treatment, depending on the patient cohort
Must not have had major surgery or radiation therapy within 14 days of starting study treatment
Subjects who have received radiation therapy, major surgery, other locoregional therapy, within 4 weeks prior to the first dose of study drug
Radiation therapy must begin within 12 weeks of surgery
Major surgery or radiation therapy within 4 weeks prior to the Baseline Visit.
> 4 weeks since prior radiation, surgery or chemotherapy
Patients who will receive radiation therapy as their primary treatment after surgery
At least 4 weeks post-surgery, and must be at least 3 months post-radiation therapy, with resolution of related toxicities
Surgery or radiation planned within 8 weeks of starting therapy
Previous treatment with surgery, radiation or hormonal therapy is allowed
Patients must be >= 3 weeks beyond treatment with a cytotoxic chemotherapy regimen, or therapeutic radiation, or major surgery; patients may have received palliative localized radiation immediately before or during treatment provided that radiation is not delivered to the only site of disease being treated under this protocol; for biologic/targeted agents patients must be >= 5 half-lives or >= 3 weeks from the last dose (whichever comes first); patients previously treated with vemurafenib monotherapy do not have to stop medication before they start on the protocol
Participants may have had any extent of prior surgery and/or chemotherapy; no prior cranial radiation therapy is allowed
> 4 weeks since prior radiation, surgery or chemotherapy
Patients must be at least 2 weeks from prior systemic therapy, radiation therapy, major surgery, or other investigational therapy, and have recovered from clinically significant toxicities of these prior treatments
Prior systemic chemotherapy, major surgery, or thoracic radiation within 3 weeks of study initiation.
Requirement for other forms of anticancer treatment while on trial, including maintenance therapy, other radiation therapy, and/or surgery.
Prior chemotherapy, immunotherapy, radiotherapy or major surgery (including radiation therapy or surgery for treatment of brain metastases) must be completed at least 3 weeks before study entry; prior PD-1 or PD-L1 therapy is acceptable
At least 4 weeks beyond treatment (chemotherapy, immunotherapy and/or radiation therapy) or major surgery and recovered from all acute toxicities.
At least 4 weeks beyond treatment (chemotherapy, immunotherapy and/or radiation therapy) or major surgery and recovered from all acute toxicities
Patients must be at least 2 weeks from major surgery, radiation therapy, participation in other investigational trials and must have recovered from clinically significant toxicities of these prior treatments
At least a 12 week interval should have elapsed between prior surgery, radiation therapy, chemotherapy or any other treatment and the first vaccination; patients should have recovered from surgery and adjuvant treatment
At least 4 weeks from prior therapy completion (including radiation and/or surgery) to starting the study treatment
Prior surgery and chemotherapy allowed, no prior radiation to the target area (breast or chest and nodes); NOTE: Radiation should occur 3-12 weeks after last chemotherapy or surgery, whichever comes last
Patients must be at least 4 weeks from radiation therapy or major surgery and have recovered from prior toxicities
Patients with intracranial metastases, which have been treated by surgery or radiation therapy, may be eligible for study provided there is no evidence of active disease and no requirement for anticonvulsant therapy or steroids following treatment
Prior major surgery or radiation therapy within 14 days of initiation of treatment
At least 12 weeks beyond stem cell transplant and 4 weeks beyond chemotherapy or\n             immunotherapy, major surgery, other experimental treatments, or radiation therapy to\n             the index lesions, and with all acute toxicities from prior therapy resolved to less\n             than Grade 2 toxicity by NCI CTC version 4.0
Subjects must have recovered from the acute side effects of any prior surgery, chemotherapy, or radiation therapy; a minimum time period at least 6 months should have elapsed from prior radiation treatment until enrollment in the study
Major surgery or radiation therapy < 4 weeks of starting study treatment
Treatment with radiation therapy, surgery, chemotherapy, or investigational therapy within 28 days prior to study entry.
Time elapsed from previous therapy must be ? 3 weeks for systemic therapy, ? 2 weeks for radiation therapy or major surgery.
Has had major surgery within 4 weeks, received radiation therapy within 2 weeks prior to randomization, or has not recovered (i.e., ? Grade 1 or at baseline) from AEs due to prior treatment.
Prior Therapy • Patients must have not received any prior therapy other than surgery, radiation and/or steroids.
Prior systemic therapy, radiation therapy, or surgery within 28 days of starting study treatment
Patients must be >/= 3 weeks beyond treatment with a cytotoxic chemotherapy regimen, or therapeutic radiation, or major surgery. Patients may have received palliative localized radiation immediately before or during treatment provided that radiation is not delivered to the only site of disease being treated under this protocol. For biologic/targeted agents patients must be >/= 5 half-lives or >/= 3 weeks form the last dose (whichever comes first).
Patients with locoregional disease that have not received appropriate standard locoregional therapy with surgery and/or radiation therapy
Patients must not have received chemotherapy, radiation therapy, or undergone major surgery within 4 weeks prior to enrollment
The patient has received chemotherapy, surgery, or radiotherapy (for therapeutic purposes) within 3 weeks of initiating study treatment (4 weeks for bevacizumab or investigational drugs) or the patient has not recovered (grade >= 2 from side effects of the previous therapy); patients who receive palliative radiation therapy can be treated immediately after completion of radiation therapy
Subjects must not have had prior surgery (biopsy allowed) or radiation therapy within 6 months of enrollment.
Prior intraabdominal, intrathoracic, vascular, spinal or intracranial surgery or radiation therapy within 4 weeks of starting treatment
Patients may have received prior radiation therapy or surgery; however, at least 14 days must have elapsed since completion of radiation therapy or surgery and patient must have only grade 2 or less adverse effects at the time of registration
Brain metastases unless documented to be controlled post completion of local therapy (surgery and/or radiation therapy) for at least four weeks prior to registration
Treatment with any of the following anti-cancer therapies:\r\n* Radiation therapy, surgery or tumor embolization within 14 days prior to the first dose of study treatment
For radiation required prior to surgery, the participant must register within 84 days of surgery. Also, participants in this situation would not be required to have additional post-mastectomy radiation therapy.
HNSCC and cSCC cannot be curable by surgery and/or radiation therapy
Patients who have received radiation therapy, radionuclide therapy or undergone surgery within certain duration (4 weeks) of enrollment
Patients must be at least 2 weeks from major surgery, radiation therapy, participation in other investigational trials and must have recovered from clinically significant toxicities of these prior treatments
Patients who have had major surgery or radiation therapy within 21 days of starting treatment
Patients must have recovered from prior treatment regimens, e.g. surgery, radiation
Major surgery or radiation therapy within four weeks of the first dose of ARQ 087
Patients must be >= 3 weeks beyond treatment with a cytotoxic chemotherapy regimen, or therapeutic radiation, or major surgery; a confirmation (written or verbal) that there is no risk of surgical complications from a patient’s surgeon has to be obtained prior to starting therapy in patients with a history of major surgery within past 6 weeks; patients may have received palliative localized radiation immediately before or during treatment provided that radiation is not delivered to the only site of disease being treated under this protocol; for biologic/targeted agents patients must be >= 5 half-lives or >= 3 weeks form the last dose (whichever comes first)
Patient must not have had radiation therapy, minor surgery, or tumor embolization with 14 days prior to the first dose of pazopanib
Patients must not have received chemotherapy, radiation therapy, or undergone major surgery within 4 weeks prior to enrollment
Major surgery or radiation therapy < 4 weeks of starting study treatment
Patients may have received prior radiation therapy or surgery; however, at least 21 days must have elapsed since completion of radiation therapy or surgery and patient must have recovered from all side effects at the time of registration
Prior treatment (major surgery, radiation therapy, chemotherapy, or other investigational drugs) received within 28 days before randomization.
Major surgery or radiation treatment < 4 weeks prior to enrollment; in addition, cannot have received radiation to the thorax or gastrointestinal tract within three months of the first dose of study treatment
Patients will be ineligible if surgery and chemotherapy was completed >= 20 weeks from the planned start date of radiation therapy or if the patient is referred for radiation therapy after a relapse of prior ipsilateral breast cancer; surgery can exceed 20 weeks if the patient undergoes chemotherapy following surgery
Major surgical procedure or any radiation therapy within 4 weeks of treatment, minimum rest period is 28 days post surgery; maximum rest period 56 days post surgery
Minimum of four weeks since any major surgery or since completion of radiation (patients should have adequately recovered from the acute toxicities of any prior therapy)
Patients must be >= 3 weeks beyond treatment with a cytotoxic chemotherapy regimen, or therapeutic radiation, or major surgery; patients may have received palliative localized radiation immediately before or during treatment provided that radiation is not delivered to the only site of disease being treated under this protocol; for biologic/targeted agents patients must be >= 5 half-lives or >= 3 weeks form the last dose (whichever comes first)
All previous therapy not associated with peripheral blood stem cell transplant, including radiation, hormonal therapy, and surgery, must have been discontinued 4 weeks prior to treatment in this study
Major surgery, locoregional therapy, or radiation therapy within four weeks of the first dose of ARQ 087
Previous treatment with definitive surgery or radiation therapy or both
Major surgery, chemotherapy, radiation therapy or other cancer therapy within 3 weeks of treatment day 1
Must be at least 4 weeks since treatment with standard or investigational chemotherapy, biochemotherapy, surgery, radiation, cytokine therapy, and 8 weeks since any monoclonal antibodies or immunotherapy, and recovered from any clinically significant toxicity experienced during treatment
Radiation therapy or surgery in the past 4 weeks
Patient with major surgery or radiotherapy within 4 weeks prior to the start of the study treatment (i.e., D1 of Cycle 1). Prior surgery or radiation therapy aimed at local palliation or attempted local disease control is permitted
TREATMENT: Patients with no more than 3 intracranial metastases, which have been definitively treated by surgery or radiation therapy may be eligible for the study, provided there is no evidence of active disease for at least 2 months and no requirement for anticonvulsant therapy or steroids following treatment
Prior treatment including surgery, chemotherapy or radiation therapy for the current primary breast cancer
Radiation and surgery within 4 weeks prior to treatment in this study
Patients in whom surgery or radiation therapy may be impractical
have stable neurologic status post administration of local therapy (surgery or radiation) for a minimum of 2 weeks following completion of the definitive therapy.
Any site of disease that is not amenable to definitively local therapy including surgery or radiation therapy
Any medical co-morbidities that would preclude surgery or radiation therapy
Must have stable neurologic status following local therapy (surgery or radiation) for at least 2 weeks after completion of the definitive therapy AND
Recovered from prior radiation therapy or surgery
Major surgery, radiation therapy or systemic anti-cancer therapy within 4 weeks of starting study treatment
Major surgery, radiation therapy, or systemic anti-cancer therapy within 4 weeks of study treatment start
Cancer progression after treatment with the following: surgery, radiation therapy and temozolomide as first line treatment with no other therapy prior to tumor recurrence.
Subjects who received any of the following within the last 14 days of initiation of study treatment: 1) Plasmapheresis, 2) Major surgery, 3) Radiation therapy, 4) Use of any anti-myeloma drug therapy
initial definitive therapy such as surgery with or without adjuvant radiation
Patients with intracranial metastases, which have been treated by surgery or radiation therapy, may be eligible for study provided there is no evidence of active disease and no requirement for anticonvulsant therapy or steroids following treatment
Have received surgery, chemotherapy, and/or radiation therapy
For stage I-III disease, patients should be 2-24 months post-completion of surgery, radiation therapy and/or chemotherapy with no further planned treatment during the 12-week study and no evidence of disease
Have not completed surgery, chemotherapy, or radiation treatment associated with their diagnosis; a washout period of a minimum of 6 weeks is required from the last anti-cancer treatment received except hormonal therapy
Definitive radiation treatment with or without concurrent chemotherapy with curative intent; treatment prior to radiation therapy is acceptable (e.g. surgery, chemotherapy)
Completion of treatment (e.g., chemotherapy, radiation therapy, surgery, etc.) for gynecologic or breast cancer 6 months or greater in the past
2 months – 10 years status post surgery, radiation and chemotherapy
Planned radiation therapy or surgery to the bone (does not include procedures performed before randomization)
Prior surgery or radiation therapy to the region of interest
Current active treatment with chemotherapy, radiation or surgery in the past 3 months or planned treatment during this study protocol period; hormonal therapy is allowed
Have undergone some type or combination of standard adjuvant treatment (surgery, chemotherapy, radiation therapy) for breast cancer
Current active treatment with chemotherapy, radiation or surgery in the past 3 months or planned treatment during this study protocol period; hormonal therapy is allowed
Major surgery or radiation treatment within 3 months
At least 2 weeks since prior chemotherapy, radiation treatment and/or surgery
Patients may have received prior radiation therapy or major surgery; however, at least 21 days prior to treatment start must have elapsed since completion of radiation therapy or major surgery and patient must have recovered from all side effects at the time of randomization
Minimum 3-week interval from last chemotherapy administration and last breast surgery to radiation
Complete response by PET achieved with pre-radiation therapy treatment (surgery or chemotherapy)
Will undergo surgery or chemo-radiation treatment
Complete response by PET achieved with pre-radiation therapy treatment (surgery or chemotherapy)
Has had chemotherapy, radiation, biological cancer therapy or major surgery within 4 weeks prior to the first dose of study treatment
Previous treatment (chemotherapy, radiation, or surgery) to both breasts, including hormone therapy